{"analyses":[{"ciLowerLimit":"0.83","ciNumSides":"TWO_SIDED","ciPctValue":"90.0","ciUpperLimit":"0.92","groupIds":["OG000","OG001"],"nonInferiorityComment":"The null hypothesis that atezolizumab SC is inferior to atezolizumab IV is rejected if the lower bound of the 2-sided 90% CI of the geometric mean ratio is ≥ the non-inferiority margin 0.8.","nonInferiorityType":"NON_INFERIORITY","paramType":"Geometric mean ratio","paramValue":"0.87"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.4","value":"3327.9"},{"groupId":"OG001","spread":"35.9","value":"2907.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"246"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg"},{"description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"From start of dosing up to Day 21 in Cycle 1 (Cycle length = 21 days)","title":"Part 2: Area Under the Concentration-Time Curve From Time Zero to 21 Days (AUC 0-21 d) at Cycle 1","type":"PRIMARY","unitOfMeasure":"micrograms day per mL (μg*day/mL)"}